ライフサイエンスコーパス: muscle disorder

1 l arthrogryposis-1 (DA-1), a severe skeletal muscle disorder.

2 tal muscle mass in many acquired and genetic muscle disorders.

3 veness of gene- and cell-based therapies for muscle disorders.

4 tential intracellular therapeutic target for muscle disorders.

5 omyosin, as needed in therapeutic design for muscle disorders.

6 new and personalized treatments for skeletal muscle disorders.

7 7 may be an important therapeutic target for muscle disorders.

8 tly being pursued as therapeutic options for muscle disorders.

9 promises for the treatment of many forms of muscle disorders.

10 and neuropsychiatric diseases, and skeletal muscle disorders.

11 sed this treatment strategy for pathological muscle disorders.

12 aging syndromes, lipodystrophy, and striated muscle disorders.

13 wasting in chronic diseases and degenerative muscle disorders.

14 fflicted with ischemic and nonischemic heart muscle disorders.

15 se channels are known to cause several human muscle disorders.

16 c population included patients with 12 other muscle disorders.

17 atments for muscle weakness in DMD and other muscle disorders.

18 ential therapeutic approach for degenerative muscle disorders.

19 tment of strabismus, nystagmus, or other eye muscle disorders.

20 oving regeneration in diverse and burdensome muscle disorders.

21 s in transcription factors cause a number of muscle disorders.

22 hem attractive models for studying mammalian muscle disorders.

23 ve skeletal muscle formation in degenerative muscle disorders.

24 of genetic therapy for DMD, as well as other muscle disorders.

25 the diagnosis, management, and treatment of muscle disorders.

26 ons learned from systemic genetic therapy of muscle disorders also should have implications for other

27 roderma myopathy is a heterogeneous group of muscle disorders among patients with underlying sclerode

28 fective therapeutic drug against involuntary muscle disorders and for pain management.

29 of clinical symptoms that include nerve and muscle disorders and red cell acanthocytosis.

30 everal ongoing clinical trials for different muscle disorders and the advances in the understanding o

31 were 8 subjects who were being evaluated for muscle disorders and who were not diagnosed as having ju

32 The primary muscle disorders are a diverse group of diseases caused

33 s causing FPLD, in contrast to those causing muscle disorders, are tightly clustered within the C-ter

34 auses nemaline myopathy, a lethal congenital muscle disorder associated with aberrant myofiber struct

35 -epimerase/ManNAc kinase) myopathy is a rare muscle disorder associated with aging and is related to

36 have DMD gene mutations but may have another muscle disorder associated with elevated neonatal creati

37 41 (KLHL41) cause nemaline myopathy, a fatal muscle disorder associated with sarcomere disarray.

38 ic right ventricular cardiomyopathy, a heart muscle disorder associated with ventricular arrhythmias,

39 (NF-kappaB) is involved in multiple skeletal muscle disorders, but how it functions in differentiatio

40 Infantile Pompe disease is a fatal genetic muscle disorder caused by a deficiency of acid alpha-glu

41 uchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin.

42 rage myopathy (MSM) is a congenital skeletal muscle disorder caused by missense mutations in the beta

43 ongenita is a temperature-sensitive skeletal muscle disorder caused by missense mutations that occur

44 nne muscular dystrophy (DMD), a degenerative muscle disorder caused by mutations in the dystrophin ge

45 (HyperKPP) is an autosomal dominant skeletal muscle disorder caused by single mutations in the SCN4A

46 arcotubular myopathy are hereditary skeletal muscle disorders caused by mutations in TRIM32.

47 (DMD) is the most common and lethal genetic muscle disorder, caused by recessive mutations in the dy

48 Dilated cardiomyopathy (DCM) is a heart muscle disorder characterized by atrial and ventricular

49 ve cardiomyopathy (RCM) is an uncommon heart muscle disorder characterized by impaired filling of the

50 Nemaline myopathy (NM) is a genetic muscle disorder characterized by muscle dysfunction and

51 Inclusion body myopathy is a progressive muscle disorder characterized by nuclear and cytoplasmic

52 (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing diff

53 y myopathies (IMs) are debilitating skeletal muscle disorders characterized by common pathological ev

54 cally and genetically heterogeneous group of muscle disorders characterized by congenital or early-on

55 ibilities for the treatment of many forms of muscle disorders characterized by impaired regeneration

56 phies (MDs) comprise a group of degenerative muscle disorders characterized by progressive muscle was

57 ystrophin gene cause the severe degenerative muscle disorder, Duchenne muscular dystrophy (DMD).

58 physiologic approach to certain drug-induced muscle disorders, especially those caused by the lipid-l

59 Inclusion body myositis, the most common muscle disorder in the elderly, is partly characterized

60 f inflammatory myopathies and those of other muscle disorders, in particular, the genetic muscular dy

61 riteria, the most common immune inflammatory muscle disorders include Dermatomyositis (DM), Polymyosi

62 ous exercise and in a spectrum of congenital muscle disorders including malignant hyperthermia.

63 ic dystrophy (DM), the most common inherited muscle disorder, is caused by a CTG expansion in the 3"-

64 ispositioned nuclei are correlated with many muscle disorders, it is not known whether this common ph

65 otonia are three autosomal dominant skeletal muscle disorders linked to the SCN4A gene encoding the a

66 The severity of the muscle disorder may vary from trivial myalgias or elevat

67 ide channel are associated with the skeletal muscle disorder myotonia congenita.

68 channels have been linked to the hereditary muscle disorder myotonia congenita.

69 to be important contributors to neuronal and muscle disorders of excitability.

70 in RyRs are associated with severe skeletal muscle disorders or triggered cardiac arrhythmias.

71 screening programs but is found in inherited muscle disorders other than DMD.

72 mogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, p

73 Nemaline myopathy (NM) is a rare congenital muscle disorder primarily affecting skeletal muscles tha

74 lar cardiomyopathy (ARVC) is a primary heart muscle disorder resulting from desmosomal protein mutati

75 causes such as celiac disease, thyroid, and muscle disorders should be considered in the differentia

76 Given this channel's involvement in other muscle disorders such as paramyotonia congenita and hype

77 al in treating nitric oxide-dependent smooth muscle disorders, such as erectile dysfunction.

78 opathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, a

79 ic paralysis (HypoPP) is a familial skeletal muscle disorder that presents with recurrent episodes of

80 lar dystrophy is a general term encompassing muscle disorders that cause weakness and wasting, typica

81 ic paralyses are a diverse group of skeletal muscle disorders that share a common pathophysiological

82 se either a cardiac or a congenital skeletal muscle disorder through different modes of inheritance.

83 range from inherited cardiac arrhythmias, to muscle disorders, to forms of diabetes.

84 d genetically heterogeneous group of primary muscle disorders where weakness and atrophy are restrict

85 eterogeneous group of genetically determined muscle disorders with a primary or predominant involveme

86 Consequently, the treatment of muscle disorders with mesoangioblasts should take into c

87 comprise a heterogeneous group of heritable muscle disorders with often difficult to interpret muscl

88 stem cell-based therapies to treat skeletal muscle disorders, with a special emphasis on muscular dy

89 NaV1.4 give rise to a heterogeneous group of muscle disorders, with gain-of-function defects causing